Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
Status:
RECRUITING
Trial end date:
2030-05-28
Target enrollment:
Participant gender:
Summary
The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and treat curtained advanced cancers, combined with low dose IL-2, which is a cytokine that activates immune cells, in advanced clear cell renal cell carcinoma and urothelial carcinoma.
Names of the study therapies involved in this study are/is:
* CIML NK cell therapy (a NK cell therapy)
* IL-2 (a type of cytokine)